Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS
Healthcare Corporation (VITAS), one of the nation’s largest
providers of end-of-life care, and Roto-Rooter, the nation’s
largest commercial and residential plumbing and drain cleaning
services provider, reported financial results for its fourth
quarter ended December 31, 2019, versus the comparable prior-year
period, as follows:
Consolidated operating results:
- Revenue increased 14.2% to $522 million
- GAAP Diluted Earnings-per-Share (EPS) of $3.96, an increase of
21.5%
- Adjusted Diluted EPS of $4.22, an increase of 26.0%
VITAS segment operating results:
- Net Patient Revenue of $340 million, an increase of 10.7%
- Average Daily Census (ADC) of 19,258, an increase of 6.1%
- Admissions of 17,479, an increase of 5.4%
- Net Income, excluding certain discrete items, of $50.1 million,
an increase of 24.5%
- Adjusted EBITDA, excluding Medicare Cap, of $70.5 million, an
increase of 27.0%
Roto-Rooter segment operating results:
- Revenue of $182 million, an increase of 21.2%
- Net Income, excluding certain discrete items, of $30.5 million,
an increase of 16.3%
- Adjusted EBITDA of $43.7 million, an increase of 20.9%
- Adjusted EBITDA margin of 24.0%, equal to the prior year
VITAS
VITAS net revenue was $340 million in the fourth quarter of
2019, which is an increase of 10.7%, when compared to the
prior-year period. This revenue increase is comprised primarily of
a geographically weighted average Medicare reimbursement rate
increase of approximately 5.5%, a 6.1% increase in days-of-care and
an increase in the Medicare Cap billing limitation that decreased
revenue 0.3%. This growth was partially offset by acuity mix shift,
fluctuations in net room and board and contractual adjustments, the
combination of which negatively impacted revenue growth
approximately 0.7%, when compared to the prior-year period.
In the fourth quarter of 2019, VITAS accrued $4.5 million in
Medicare Cap billing limitations. This compares to the prior-year
Medicare Cap billing limitation of $3.5 million.
VITAS currently has 30 Medicare provider numbers. On a 12-month
trailing basis, 23 of these provider numbers have a Medicare Cap
cushion of 10% or greater, three provider numbers have a cap
cushion between 0% and 5%, and four provider numbers have a
Medicare Cap billing limitation.
Average revenue per patient per day in the fourth quarter of
2019 was $198.48, which is 5.0% above the prior-year period.
Reimbursement for routine home care and high acuity care averaged
$164.62 and $996.82, respectively. During the quarter, high acuity
days-of-care were 4.1% of total days of care, 11-basis points less
than the prior-year quarter. This 11-basis point mix shift in high
acuity days-of-care reduced the increase in average revenue per
patient per day from 5.5% to 5.0% in the quarter.
The fourth quarter 2019 gross margin, excluding Medicare Cap,
was 26.3%, which is a 204-basis point margin improvement when
compared to the fourth quarter of 2018.
Selling, general and administrative expense was $21.2 million in
the fourth quarter of 2019, which is an increase of 3.9% compared
to the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap,
totaled $70.5 million in the quarter, an increase of 27.0%.
Adjusted EBITDA margin, excluding Medicare Cap, was 20.5% in the
quarter, which is a 259-basis point margin improvement when
compared to the prior-year period.
Roto-Rooter
Roto-Rooter generated quarterly revenue of $182 million for the
fourth quarter of 2019, an increase of $31.9 million, or 21.2%,
over the prior-year quarter. On a unit for unit basis, which
excludes the Oakland and HSW acquisitions completed in July and
September 2019, respectively, Roto-Rooter generated quarterly
revenue of $162 million for the fourth quarter of 2019, an increase
of 7.9%, over the prior-year quarter.
Including acquisitions, total commercial revenue increased
26.4%. This aggregate commercial revenue growth consisted of drain
cleaning revenue expanding 34.9%, commercial plumbing and
excavation increasing 25.2%, and commercial water restoration
declining 8.8%.
Excluding acquisitions, commercial drain cleaning revenue
increased 7.1%, commercial plumbing and excavation declined 0.1%,
and commercial water restoration declined 17.4%. Commercial water
restoration represents approximately 10% of total water restoration
service revenue. Overall, commercial revenue excluding acquisitions
increased 1.2%.
Including acquisitions, total residential revenue increased
19.4%. This aggregate residential revenue growth consisted of
residential drain cleaning increasing 25.5%, plumbing and
excavation expanding 18.1%, and residential water restoration
increasing 16.3%.
Excluding acquisitions, residential drain cleaning increased
10.1%, plumbing and excavation increased 7.4%, and residential
water restoration increased 14.6%. Overall, residential sales
excluding acquisitions increased 9.5%.
Roto-Rooter’s gross margin in the quarter was 48.6%, a 15-basis
point decline when compared to the fourth quarter of 2018. Adjusted
EBITDA in the fourth quarter of 2019 totaled $43.7 million, an
increase of 20.9%. The Adjusted EBITDA margin in the quarter was
24.0% which is equivalent to the prior year.
Chemed
Consolidated
As of December 31, 2019, Chemed had total cash and cash
equivalents of $6.2 million and long-term debt of $90 million.
In June 2018, Chemed entered into a five-year Amended and
Restated Credit Agreement that consists of a $450 million revolving
credit facility. The interest rate on this facility has a floating
rate that is currently LIBOR plus 100-basis points. At December 31,
2019, the Company had approximately $322 million of undrawn
borrowing capacity under this credit agreement.
During the quarter, the Company repurchased 50,000 shares of
Chemed stock for $20.7 million which equates to a cost per share of
$414.11. As of December 31, 2019, there was approximately $104
million of remaining share repurchase authorization under this
plan.
Chemed restarted its share repurchase program in 2007. Since
that time Chemed has repurchased over 14.1 million shares,
aggregating approximately $1.2 billion at an average share cost of
$85.93. Including dividends over this period, Chemed has returned
approximately $1.4 billion to shareholders.
Guidance for
2020
Revenue growth for VITAS in 2020, prior to Medicare Cap, is
estimated to be in the range of 8.5% to 9.5%. Admissions and
Average Daily Census in 2020 are estimated to expand approximately
3.5% to 4.5%. High acuity days-of-care are estimated at 4.1% of
total 2020 days-of-care. Full-year Adjusted EBITDA margin, prior to
Medicare Cap, is estimated to be 18.7% to 19.0%. We are currently
estimating $18 million for Medicare Cap billing limitations for
calendar year 2020.
Roto-Rooter is forecasted to achieve full-year 2020 revenue
growth of 13.0% to 14.0%. This revenue estimate is based upon unit
for unit revenue growth of 4.0% to 5.0% in core plumbing and drain
cleaning services, continued but slowing revenue growth from water
restoration services, combined with 12-months of revenue in the
Oakland and HSW acquisitions. Roto-Rooter’s Adjusted EBITDA margin
for 2020 is estimated to be in the range of 23.0% to 23.5%.
Based upon the above, full-year 2020 adjusted earnings per
diluted share, excluding non-cash expense for stock options, tax
benefits from stock options, costs related to litigation,
intangible amortization of reacquired franchise rights and other
discrete items, is estimated to be in the range of $16.20 to
$16.50. This 2020 guidance assumes an effective corporate tax rate
of 25.2%. Chemed’s 2019 reported adjusted earnings per diluted
share was $13.96.
Conference Call
Chemed will host a conference call and webcast at 10 a.m., ET,
on Wednesday, February 19, 2020, to discuss the Company's quarterly
results and to provide an update on its business. The dial-in
number for the conference call is (844) 743-2500 for U.S. and
Canadian participants and +1 (661) 378-9533 for international
participants. The Conference ID is 4939797. A live webcast of the
call can be accessed on Chemed's website at www.chemed.com by
clicking on Investor Relations Home.
A taped replay of the conference call will be available
beginning approximately 24 hours after the call's conclusion. It
can be accessed by dialing (855) 859-2056 for U.S. and Canadian
callers and +1 (404) 537-3406 for international callers and will be
available for one week following the live call. The replay
Conference ID is 4939797. An archived webcast will also be
available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily
hospice services to approximately 19,000 patients with severe,
life-limiting illnesses. This type of care is focused on making the
terminally ill patient's final days as comfortable and pain-free as
possible.
Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter.
Roto-Rooter provides plumbing, drain cleaning, and water cleanup
services through company-owned branches, independent contractors
and franchisees in the United States and Canada. Roto-Rooter also
has licensed master franchisees in the republics of Indonesia and
Singapore, and the Philippines.
This press release contains information about Chemed’s EBITDA,
Adjusted EBITDA and Adjusted Diluted EPS, which are not measures
derived in accordance with GAAP and which exclude components that
are important to understanding Chemed’s financial performance. In
reporting its operating results, Chemed provides EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company’s operating results, compare its
operating performance with that of similar companies that have
different capital structures and evaluate its ability to meet its
future debt service, capital expenditures and working capital
requirements. Chemed’s management similarly uses EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS to assist it in evaluating the
performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures
also help Chemed’s management to estimate the resources required to
meet Chemed’s future financial obligations and expenditures.
Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should
not be considered in isolation or as a substitute for comparable
measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by
service revenue and sales. A reconciliation of Chemed’s net income
to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is
presented in the tables following the text of this press
release.
Forward-Looking Statements
Certain statements contained in this press release and the
accompanying tables are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
The words "believe," "expect," "hope," "anticipate," "plan" and
similar expressions identify forward-looking statements, which
speak only as of the date the statement was made. Chemed does not
undertake and specifically disclaims any obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. These
statements are based on current expectations and assumptions and
involve various risks and uncertainties, which could cause Chemed's
actual results to differ from those expressed in such
forward-looking statements.
These risks and uncertainties arise from, among other things,
possible changes in regulations governing the hospice care or
plumbing and drain cleaning industries; periodic changes in
reimbursement levels and procedures under Medicare and Medicaid
programs; difficulties predicting patient length of stay and
estimating potential Medicare reimbursement obligations; challenges
inherent in Chemed's growth strategy; the current shortage of
qualified nurses, other healthcare professionals and licensed
plumbing and drain cleaning technicians; Chemed’s dependence on
patient referral sources; and other factors detailed under the
caption "Description of Business by Segment" or "Risk Factors" in
Chemed’s most recent report on form 10-Q or 10-K and its other
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on such forward-looking
statements and there are no assurances that the matters contained
in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED
STATEMENTS OF INCOME (in thousands, except per share
data)(unaudited)
Three Months Ended December
31,
For the Years Ended December
31,
2019
2018
2019
2018
Service revenues and sales
522,324
$
457,507
$
1,938,555
$
1,782,648
Cost of services provided and goods sold
347,355
312,054
1,321,126
1,227,644
Selling, general and administrative expenses (aa)
83,291
66,735
305,712
271,209
Depreciation
11,126
9,822
40,870
38,464
Amortization
2,969
303
4,335
399
Other operating expenses
131
1,212
9,132
1,300
Total costs and expenses
444,872
390,126
1,681,175
1,539,016
Income from operations
77,452
67,381
257,380
243,632
Interest expense
(1,133
)
(1,177
)
(4,535
)
(4,990
)
Other income--net (bb)
3,276
(3,398
)
8,764
958
Income before income taxes
79,595
62,806
261,609
239,600
Income taxes
(14,015
)
(8,478
)
(41,686
)
(34,056
)
Net income
$
65,580
$
54,328
$
219,923
$
205,544
Earnings Per Share Net income
$
4.09
$
3.39
$
13.77
$
12.80
Average number of shares outstanding
16,022
16,026
15,969
16,059
Diluted Earnings Per Share Net income
$
3.96
$
3.26
$
13.31
$
12.23
Average number of shares outstanding
16,565
16,670
16,527
16,803
(aa) Selling, general and administrative ("SG&A")
expenses comprise (in thousands):
Three Months Ended December
31,
For the Years Ended December
31,
2019
2018
2019
2018
SG&A expenses before long-term incentive compensation and the
impact of market value adjustments related to deferred compensation
plans
$
77,053
$
68,034
$
289,828
$
264,304
Market value adjustments related to deferred compensation trusts
3,160
(3,541
)
8,254
287
Long-term incentive compensation
3,078
2,242
7,630
6,618
Total SG&A expenses
$
83,291
$
66,735
$
305,712
$
271,209
(bb) Other income--net comprises (in thousands):
Three Months Ended December
31,
For the Years Ended December
31,
2019
2018
2019
2018
Market value adjustments related to deferred compensation trusts
$
3,160
$
(3,541
)
$
8,254
$
287
Interest income
126
143
513
671
Other
(10
)
-
(3
)
-
Total other income--net
$
3,276
$
(3,398
)
$
8,764
$
958
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS (in thousands, except per share
data)(unaudited)
December 31,
2019
2018
Assets Current assets Cash and cash equivalents
$
6,158
$
4,831
Accounts receivable less allowances
143,827
119,504
Inventories
7,462
5,705
Prepaid income taxes
10,074
10,646
Prepaid expenses
23,150
19,154
Total current assets
190,671
159,840
Investments of deferred compensation plans held in trust
77,446
65,624
Properties and equipment, at cost less accumulated depreciation
175,763
162,033
Lease right of use asset
111,652
-
Identifiable intangible assets less accumulated amortization
126,370
68,253
Goodwill
577,367
510,570
Other assets
9,048
9,209
Total Assets
$
1,268,317
$
975,529
Liabilities Current liabilities Accounts payable
$
51,101
$
50,150
Accrued insurance
50,328
46,095
Accrued compensation
70,814
63,329
Accrued legal
6,941
1,857
Short-term lease liability
39,280
-
Other current liabilities
43,756
30,239
Total current liabilities
262,220
191,670
Deferred income taxes
18,504
21,598
Long-term debt
90,000
89,200
Deferred compensation liabilities
76,446
64,616
Long-term lease liability
86,656
-
Other liabilities
7,883
17,111
Total Liabilities
541,709
384,195
Stockholders' Equity Capital stock
35,811
35,311
Paid-in capital
860,671
774,358
Retained earnings
1,425,752
1,225,617
Treasury stock, at cost
(1,597,940
)
(1,446,296
)
Deferred compensation payable in Company stock
2,314
2,344
Total Stockholders' Equity
726,608
591,334
Total Liabilities and Stockholders' Equity
$
1,268,317
$
975,529
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (in
thousands)(unaudited)
For the Years Ended December
31,
2019
2018
Cash Flows from Operating Activities Net income
$
219,923
$
205,544
Adjustments to reconcile net income to net cash provided by
operating activities: Depreciation and amortization
45,205
38,863
Stock option expense
14,831
12,611
Litigation settlement
6,000
-
Noncash long-term incentive compensation
5,740
5,405
(Benefit)/provision for deferred income taxes
(2,770
)
5,187
Loss on sale of transportation equipment
2,266
-
Noncash directors' compensation
767
766
Amortization of debt issuance costs
306
441
Amortization of restricted stock awards
-
446
Changes in operating assets and liabilities, excluding amounts
acquired in business combinations: Increase in accounts receivable
(19,247
)
(5,570
)
Increase in inventories
(1,757
)
(351
)
Increase in prepaid expenses
(3,491
)
(2,665
)
Increase in accounts payable and other current liabilities
28,417
8,935
Change in current income taxes
161
18,898
Net change in lease assets and liabilities
3,108
-
Increase in other assets
(11,963
)
(5,544
)
Increase in other liabilities
12,354
3,451
Other sources
1,399
721
Net cash provided by operating activities
301,249
287,138
Cash Flows from Investing Activities Business combinations,
net of cash acquired
(138,010
)
(53,177
)
Capital expenditures
(53,022
)
(52,872
)
Other sources
272
824
Net cash used by investing activities
(190,760
)
(105,225
)
Cash Flows from Financing Activities Proceeds from revolving
line of credit
482,900
469,550
Payments on revolving line of credit
(482,100
)
(406,550
)
Purchases of treasury stock
(92,631
)
(158,884
)
Proceeds from exercise of stock options
34,380
32,412
Capital stock surrendered to pay taxes on stock-based compensation
(28,474
)
(27,548
)
Dividends paid
(19,788
)
(18,662
)
Change in cash overdrafts payable
(3,927
)
(1,531
)
Payments on other long-term debt
-
(75,000
)
Debt issuance costs
-
(1,052
)
Other sources/(uses)
478
(938
)
Net cash used by financing activities
(109,162
)
(188,203
)
Increase/(decrease) in Cash and Cash Equivalents
1,327
(6,290
)
Cash and cash equivalents at beginning of year
4,831
11,121
Cash and cash equivalents at end of year
$
6,158
$
4,831
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME FOR THE THREE MONTHS
ENDED DECEMBER 31, 2019 AND 2018 (in thousands)(unaudited)
Chemed
VITAS
Roto-Rooter
Corporate
Consolidated
2019
Service revenues and sales (a)
$
339,905
$
182,419
$
-
$
522,324
Cost of services provided and goods sold
253,659
93,696
-
347,355
Selling, general and administrative expenses (a)
21,162
46,198
15,931
83,291
Depreciation
5,341
5,747
38
11,126
Amortization
18
2,951
-
2,969
Other operating expense
25
106
-
131
Total costs and expenses
280,205
148,698
15,969
444,872
Income/(loss) from operations
59,700
33,721
(15,969
)
77,452
Interest expense
(19
)
(72
)
(1,042
)
(1,133
)
Intercompany interest income/(expense)
4,740
1,543
(6,283
)
-
Other income—net
76
40
3,160
3,276
Income/(loss) before income taxes
64,497
35,232
(20,134
)
79,595
Income taxes (a)
(15,075
)
(7,823
)
8,883
(14,015
)
Net income/(loss)
$
49,422
$
27,409
$
(11,251
)
$
65,580
2018
Service revenues and sales (b)
$
306,985
$
150,522
$
-
$
457,507
Cost of services provided and goods sold
234,971
77,083
-
312,054
Selling, general and administrative expenses (b)
20,363
37,563
8,809
66,735
Depreciation
4,935
4,847
40
9,822
Amortization
12
291
-
303
Other operating expense
1,114
98
-
1,212
Total costs and expenses
261,395
119,882
8,849
390,126
Income/(loss) from operations
45,590
30,640
(8,849
)
67,381
Interest expense
(22
)
(64
)
(1,091
)
(1,177
)
Intercompany interest income/(expense)
3,308
1,678
(4,986
)
-
Other income—net
110
32
(3,540
)
(3,398
)
Income/(loss) before income taxes
48,986
32,286
(18,466
)
62,806
Income taxes (b)
(9,860
)
(6,375
)
7,757
(8,478
)
Net income/(loss)
$
39,126
$
25,911
$
(10,709
)
$
54,328
The "Footnotes to Financial Statements" are integral parts
of this financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES CONSOLIDATING STATEMENTS OF INCOME FOR THE
YEARS ENDED DECEMBER 31, 2019 AND 2018 (in
thousands)(unaudited)
Chemed
VITAS
Roto-Rooter
Corporate
Consolidated
2019
Service revenues and sales (a)
$
1,281,184
$
657,371
$
-
$
1,938,555
Cost of services provided and goods sold
982,056
339,070
-
1,321,126
Selling, general and administrative expenses (a)
86,345
166,934
52,433
305,712
Depreciation
19,984
20,730
156
40,870
Amortization
71
4,264
-
4,335
Other operating expense (a)
6,546
320
2,266
9,132
Total costs and expenses
1,095,002
531,318
54,855
1,681,175
Income/(loss) from operations
186,182
126,053
(54,855
)
257,380
Interest expense
(169
)
(345
)
(4,021
)
(4,535
)
Intercompany interest income/(expense)
18,135
8,152
(26,287
)
-
Other income—net
385
126
8,253
8,764
Income/(loss) before income taxes
204,533
133,986
(76,910
)
261,609
Income taxes (a)
(48,711
)
(30,276
)
37,301
(41,686
)
Net income/(loss)
$
155,822
$
103,710
$
(39,609
)
$
219,923
2018
Service revenues and sales (b)
$
1,197,562
$
585,086
$
-
$
1,782,648
Cost of services provided and goods sold
928,306
299,338
-
1,227,644
Selling, general and administrative expenses (b)
81,969
145,683
43,557
271,209
Depreciation
19,688
18,629
147
38,464
Amortization
12
387
-
399
Other operating expense (b)
1,130
170
-
1,300
Total costs and expenses
1,031,105
464,207
43,704
1,539,016
Income/(loss) from operations
166,457
120,879
(43,704
)
243,632
Interest expense
(175
)
(319
)
(4,496
)
(4,990
)
Intercompany interest income/(expense)
12,832
6,908
(19,740
)
-
Other income—net
579
93
286
958
Income/(loss) before income taxes
179,693
127,561
(67,654
)
239,600
Income taxes (b)
(40,847
)
(28,850
)
35,641
(34,056
)
Net income/(loss)
$
138,846
$
98,711
$
(32,013
)
$
205,544
The "Footnotes to Financial Statements" are integral parts
of this financial information.
CHEMED CORPORATION AND
SUBSIDIARY COMPANIES CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED DECEMBER 31, 2019 AND 2018 (in
thousands)(unaudited)
Chemed
VITAS
Roto-Rooter
Corporate
Consolidated
2019
Net income/(loss)
$
49,422
$
27,409
$
(11,251
)
$
65,580
Add/(deduct): Interest expense
19
72
1,042
1,133
Income taxes
15,075
7,823
(8,883
)
14,015
Depreciation
5,341
5,747
38
11,126
Amortization
18
2,951
-
2,969
EBITDA
69,875
44,002
(19,054
)
94,823
Add/(deduct): Intercompany interest expense/(income)
(4,740
)
(1,543
)
6,283
-
Interest income
(84
)
(42
)
-
(126
)
Stock option expense
-
-
4,102
4,102
Long-term incentive compensation
-
-
3,079
3,079
Acquisition expense
-
1,286
50
1,336
Medicare cap sequestration adjustment
919
-
-
919
Adjusted EBITDA
$
65,970
$
43,703
$
(5,540
)
$
104,133
2018
Net income/(loss)
$
39,126
$
25,911
$
(10,709
)
$
54,328
Add/(deduct): Interest expense
22
64
1,091
1,177
Income taxes
9,860
6,375
(7,757
)
8,478
Depreciation
4,935
4,847
40
9,822
Amortization
12
291
-
303
EBITDA
53,955
37,488
(17,335
)
74,108
Add/(deduct): Intercompany interest expense/(income)
(3,308
)
(1,678
)
4,986
-
Interest income
(111
)
(32
)
-
(143
)
Stock option expense
-
-
3,251
3,251
Long-term incentive compensation
-
-
2,242
2,242
Litigation settlement costs
1,000
-
-
1,000
Medicare cap sequestration adjustment
456
-
-
456
Acquisition expense
32
371
-
403
Adjusted EBITDA
$
52,024
$
36,149
$
(6,856
)
$
81,317
The "Footnotes to Financial Statements" are integral parts of this
financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES CONSOLIDATING SUMMARIES OF EBITDA FOR THE
YEARS ENDED DECEMBER 31, 2019 AND 2018 (in
thousands)(unaudited)
Chemed
VITAS
Roto-Rooter
Corporate
Consolidated
2019
Net income/(loss)
$
155,822
$
103,710
$
(39,609
)
$
219,923
Add/(deduct): Interest expense
169
345
4,021
4,535
Income taxes
48,711
30,276
(37,301
)
41,686
Depreciation
19,984
20,730
156
40,870
Amortization
71
4,264
-
4,335
EBITDA
224,757
159,325
(72,733
)
311,349
Add/(deduct): Intercompany interest expense/(income)
(18,135
)
(8,152
)
26,287
-
Interest income
(380
)
(133
)
-
(513
)
Stock option expense
-
-
14,831
14,831
Long-term incentive compensation
-
-
7,630
7,630
Litigation settlement
6,000
-
-
6,000
Acquisition Expense
-
4,664
170
4,834
Medicare cap sequestration adjustment
3,982
-
-
3,982
Loss on sale of transportation equipment
-
-
2,266
2,266
Non cash ASC 842 expenses/(benefit)
656
55
(163
)
548
Adjusted EBITDA
$
216,880
$
155,759
$
(21,712
)
$
350,927
2018
Net income/(loss)
$
138,846
$
98,711
$
(32,013
)
$
205,544
Add/(deduct): Interest expense
175
319
4,496
4,990
Income taxes
40,847
28,850
(35,641
)
34,056
Depreciation
19,688
18,629
147
38,464
Amortization
12
387
-
399
EBITDA
199,568
146,896
(63,011
)
283,453
Add/(deduct): Intercompany interest expense/(income)
(12,832
)
(6,908
)
19,740
-
Interest (income)/expense
(580
)
(92
)
1
(671
)
Stock option expense
-
-
12,611
12,611
Long-term incentive compensation
-
-
6,618
6,618
Medicare cap sequestration adjustment
1,496
-
-
1,496
Litigation settlement costs
796
-
-
796
Acquisition expense
209
548
-
757
Amortization of stock awards
107
100
239
446
Adjusted EBITDA
$
188,764
$
140,544
$
(23,802
)
$
305,506
The "Footnotes to Financial Statements" are integral parts of this
financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES RECONCILIATION OF ADJUSTED NET INCOME (in
thousands, except per share data)(unaudited)
Three Months Ended December
31,
For the Years Ended December
31,
2019
2018
2019
2018
Net income as reported
$
65,580
$
54,328
$
219,923
$
205,544
Add/(deduct) pre-tax cost of: Stock option expense
4,102
3,251
14,831
12,611
Long-term incentive compensation
3,079
2,242
7,630
6,618
Litigation settlement
-
1,000
6,000
796
Acquisition expense
1,336
403
4,834
757
Medicare cap sequestration adjustments
919
456
3,982
1,496
Amortization of acquired and cancelled franchise agreements
2,861
-
3,964
-
Loss on sale of transportation equipment
-
-
2,266
-
Non cash ASC 842 expenses
-
-
548
-
Add/(deduct) tax impacts: Tax impact of the above pre-tax
adjustments (1)
(2,567
)
(1,527
)
(9,328
)
(4,586
)
Excess tax benefits on stock compensation
(5,440
)
(4,244
)
(24,177
)
(22,862
)
Adjusted net income
$
69,870
$
55,909
$
230,473
$
200,374
Diluted Earnings Per Share As Reported Net income
$
3.96
$
3.26
$
13.31
$
12.23
Average number of shares outstanding
16,565
16,670
16,527
16,803
Adjusted Diluted Earnings Per Share Adjusted net income
$
4.22
$
3.35
$
13.95
$
11.93
Average number of shares outstanding
16,565
16,670
16,527
16,803
(1) The tax impact of pre-tax adjustments was calculated
using the effective tax rate of the operating unit for which each
adjustment is associated. The "Footnotes to Financial
Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES OPERATING
STATISTICS FOR VITAS SEGMENT (unaudited)
Three Months Ended December
31,
For the Years Ended December
31,
OPERATING STATISTICS
2019
2018
2019
2018
Net revenue ($000) (c) Homecare
$
275,976
$
261,972
$
1,076,025
$
1,010,518
Inpatient
30,857
20,874
99,920
82,677
Continuous care
40,997
30,834
133,473
122,498
Other
3,825
1,986
10,433
7,831
Subtotal
$
351,655
$
315,666
$
1,319,851
$
1,223,524
Room and board, net
(3,260
)
(2,191
)
(11,359
)
(10,054
)
Contractual allowances
(3,990
)
(3,036
)
(14,893
)
(11,785
)
Medicare cap allowance
(4,500
)
(3,454
)
(12,415
)
(4,123
)
Net Revenue
$
339,905
$
306,985
$
1,281,184
$
1,197,562
Net revenue as a percent of total before Medicare cap allowance
Homecare
78.5
%
83.0
%
81.5
%
82.6
%
Inpatient
8.8
6.6
7.6
6.8
Continuous care
11.7
9.8
10.1
10.0
Other
1.0
0.6
0.8
0.6
Subtotal
100.0
100.0
100.0
100.0
Room and board, net
(0.9
)
(0.7
)
(0.9
)
(0.8
)
Contractual allowances
(1.1
)
(1.0
)
(1.1
)
(1.1
)
Medicare cap allowance
(1.3
)
(1.1
)
(0.9
)
(0.2
)
Net Revenue
96.7
%
97.2
%
97.1
%
97.9
%
Average daily census ("ADC") (days) Homecare
14,972
14,062
14,626
13,652
Nursing home
3,461
3,297
3,396
3,298
Routine homecare
18,433
17,359
18,022
16,950
Inpatient
375
326
366
327
Continuous care
450
464
458
465
Total
19,258
18,149
18,846
17,742
Total Admissions
17,479
16,579
69,859
68,119
Total Discharges
17,575
16,623
68,857
66,868
Average length of stay (days)
95.2
92.6
92.6
89.9
Median length of stay (days)
16.0
17.0
16.0
17.0
ADC by major diagnosis Cerebro
35.8
%
35.8
%
36.0
%
36.3
%
Neurological
21.1
18.6
20.6
19.0
Cancer
12.8
13.7
12.9
13.7
Cardio
16.2
16.3
16.5
16.4
Respiratory
8.1
8.0
8.1
8.2
Other
6.0
7.6
5.9
6.4
Total
100.0
%
100.0
%
100.0
%
100.0
%
Admissions by major diagnosis Cerebro
21.9
%
20.9
%
21.1
%
21.8
%
Neurological
12.9
11.5
12.6
11.4
Cancer
29.2
31.1
29.2
30.2
Cardio
14.7
14.6
15.5
15.4
Respiratory
10.5
10.1
11.0
10.9
Other
10.8
11.8
10.6
10.3
Total
100.0
%
100.0
%
100.0
%
100.0
%
Estimated uncollectible accounts as a percent of revenues
1.2
%
1.0
%
1.2
%
1.0
%
Accounts receivable -- Days of revenue outstanding- excluding
unapplied Medicare payments
35.4
35.0
n.a.
n.a.
Days of revenue outstanding- including unapplied Medicare payments
27.2
24.6
n.a.
n.a.
The "Footnotes to Financial Statements" are integral parts of this
financial information.
CHEMED CORPORATION AND SUBSIDIARY
COMPANIES FOOTNOTES TO FINANCIAL STATEMENTS FOR THE
THREE MONTHS AND YEARS ENDED DECEMBER 31, 2019 AND 2018
(unaudited)
(a)
Included in the results of
operations for 2019 are the following significant credits/(charges)
which may not be indicative of ongoing operations
(in thousands):
Three Months Ended December
31, 2019
VITAS
Roto-Rooter
Corporate
Consolidated
Service revenues and sales: Medicare cap sequestration adjustment
$
(919
)
$
-
$
-
$
(919
)
Selling, general and administrative expenses: Stock option expense
-
-
(4,102
)
(4,102
)
Long-term incentive compensation
-
-
(3,079
)
(3,079
)
Amortization of acquired and cancelled franchise agreements
-
(2,861
)
-
(2,861
)
Acquisition expense
-
(1,286
)
(50
)
(1,336
)
Pretax impact on earnings
(919
)
(4,147
)
(7,231
)
(12,297
)
Excess tax benefits on stock compensation
-
-
5,440
5,440
Income tax benefit on the above
233
1,101
1,233
2,567
After-tax impact on earnings
$
(686
)
$
(3,046
)
$
(558
)
$
(4,290
)
For the Year Ended December
31, 2019
VITAS
Roto-Rooter
Corporate
Consolidated
Service revenues and sales: Medicare cap sequestration adjustment
$
(3,982
)
$
-
$
-
$
(3,982
)
Selling, general and administrative expenses: Stock option expense
-
-
(14,831
)
(14,831
)
Long-term incentive compensation
-
-
(7,630
)
(7,630
)
Acquisition expense
-
(4,664
)
(170
)
(4,834
)
Amortization of acquired and cancelled franchise agreements
-
(3,964
)
-
(3,964
)
Non cash ASC 842 (expenses)/benefit
(656
)
(55
)
163
(548
)
Other operating expenses: Litigation settlement
(6,000
)
-
-
(6,000
)
Loss on sale of transportation equipment
-
-
(2,266
)
(2,266
)
Pretax impact on earnings
(10,638
)
(8,683
)
(24,734
)
(44,055
)
Excess tax benefits on stock compensation
-
-
24,177
24,177
Income tax benefit on the above
2,708
2,301
4,319
9,328
After-tax impact on earnings
$
(7,930
)
$
(6,382
)
$
3,762
$
(10,550
)
(b)
Included in the results of
operations for 2018 are the following significant credits/(charges)
which may not be indicative of ongoing operations
(in thousands):
Three Months Ended December
31, 2018
VITAS
Roto-Rooter
Corporate
Consolidated
Service revenues and sales: Medicare cap sequestration adjustment
$
(456
)
$
-
$
-
$
(456
)
Selling, general and administrative expenses: Stock option expense
-
-
(3,251
)
(3,251
)
Long-term incentive compensation
-
-
(2,242
)
(2,242
)
Acquisition expense
(32
)
(371
)
-
(403
)
Other operating expenses: Litigation settlement
(1,000
)
-
-
(1,000
)
Pretax impact on earnings
(1,488
)
(371
)
(5,493
)
(7,352
)
Excess tax benefits on stock compensation
-
-
4,244
4,244
Income tax benefit on the above
381
98
1,048
1,527
After-tax impact on earnings
$
(1,107
)
$
(273
)
$
(201
)
$
(1,581
)
For the Year Ended December
31, 2018
VITAS
Roto-Rooter
Corporate
Consolidated
Service revenues and sales: Medicare cap sequestration adjustment
$
(1,496
)
$
-
$
-
$
(1,496
)
Selling, general and administrative expenses: Stock option expense
-
-
(12,611
)
(12,611
)
Long-term incentive compensation
-
-
(6,618
)
(6,618
)
Acquisition expense
(209
)
(548
)
-
(757
)
Other operating expenses: Litigation settlement
(796
)
-
-
(796
)
Pretax impact on earnings
(2,501
)
(548
)
(19,229
)
(22,278
)
Excess tax benefits on stock compensation
-
-
22,862
22,862
Income tax benefit on the above
637
145
3,804
4,586
After-tax impact on earnings
$
(1,864
)
$
(403
)
$
7,437
$
5,170
(c) VITAS has 12 large (greater than 450 ADC), 20 medium
(greater than 200 but less than 450 ADC) and 16 small (less than
200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers,
on a 12-month trailing basis, 23 provider numbers have a Medicare
cap cushion of 10% or greater, three provider numbers have a cap
cushion between 0% and 5%, and four provider numbers have a
Medicare cap liability.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200218006005/en/
David P. Williams (513) 762-6901
Chemed (NYSE:CHE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chemed (NYSE:CHE)
Historical Stock Chart
From Apr 2023 to Apr 2024